The choice of the insulin basal rate regimen at initiation of insulin pump therapy in routine clinical practice

Cover Page

Cite item


Background: Numbers of patients with diabetes mellitus using insulin pumps have been increasing every year. Successful achievement of glycemic targets with continuous subcutaneous insulin infusion (CSII) is based on an adequate basal rate of infusion, carbohydrate coefficient and insulin sensitivity index. There are two approaches to basal insulin infusion rate, namely the flat one and the circadian; however, at present there is no convincing data on which one should be chosen at the start of insulin pump therapy.

Aim: To compare two regimens of basal insulin infusion rate at initiation of insulin pump therapy in routine clinical practice.

Materials and methods: We analyzed data from 120 patients with Type 1 diabetes mellitus, who were switched on insulin pump therapy in the Department of Endocrinology from 2017 to 2018. At initiation of CSII, 60 patients used the flat basal rate profile and the other 60 patients used the circadian basal rate, calculated with the Renner's scale. Safety of the two basal rate regimens was assessed based on glucose variability measured with continuous glucose monitoring during the first two days after the start of insulin pump therapy.

Results: Mean (± SD) coefficients of variation in the groups with circadian and flat basal rate at Day  1 were 31.06±12.13 and 32.74±10.7, respectively (p=0.423); at Day 2, 26.78±11.27 and 28.83±10.7 (p=0.309). Median [Q1; Q3] areas under glucose curve (AUC) values above the glucose targets in the groups with circadian and flat basal rate at Day 1 were 0.37 [0.03; 0.89] and 0.48 [0.08; 1.75], respectively, at Day 2 0.44 [0.03; 1.57] and 0.31 [0.1; 1.5], respectively (p>0.05). Median glucose AUC values below the goal in groups with circadian basal rate and flat basal rate on the first day were 0.01 [0; 0.06] and 0.02 [0; 0.1], respectively (p=0.855), on the second day – 0.00 [0; 0.01] and 0.00 [0; 0.02], respectively (р=0.085). We also haven’t found any between-group differences in the prevalence of glucose deviations below and above the target, as well as in the time spent in normoglycaemia.

Conclusion: The comparative analysis of two basal insulin rate regimens in Type 1 diabetic patients switched to insulin pump therapy has shown no significant differences between them. The use of Renner’s scale has no clinical advantages over the fixed basal insulin regimen at initiation of insulin pump therapy in adults.

About the authors

I. A. Barsukov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
ORCID iD: 0000-0002-1889-8555

Ilya A. Barsukov – MD, PhD, Associate Professor, Senior Research Fellow, Department of Therapeutic Endocrinology

61/2–9 Shchepkina ul., Moscow, 129110

Russian Federation

A. A. Demina

Moscow Regional Research and Clinical Institute (MONIKI)

ORCID iD: 0000-0002-7742-5782

Anna A. Demina – Postgraduate Student, Chair of Endocrinology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. V. Dreval

Moscow Regional Research and Clinical Institute (MONIKI)

ORCID iD: 0000-0002-3135-9003

Alexandr V. Dreval – MD, PhD, Professor, Head of Department of Therapeutic Endocrinology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation


  1. Chow N, Shearer D, Tildesley HG, Aydin Plaa J, Pottinger B, Pawlowska M, White A, Priestman A, Ross SA, Tildesley HD. Determining starting basal rates of insulin infusion for insulin pump users: a comparison between methods. BMJ Open Diabetes Res Care. 2016;4(1):e000145. doi: 10.1136/bmjdrc-2015-000145.
  2. Bruttomesso D, Costa S, Baritussio A. Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy. Diabetes Metab Res Rev. 2009;25(2): 99–111. doi: 10.1002/dmrr.931.
  3. Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C. Consensus Statement by the American Association of Clinical Endocrinologists/ American College of Endocrinology insulin pump management task force. Endocr Pract. 2014;20(5):463–489. doi: 10.4158/EP14145.PS.
  4. Almogbel E. Impact of insulin pump therapy on glycemic control among adult Saudi type-1 diabetic patients. An interview-based case-control study. J Family Med Prim Care. 2020;9(2):1013–1019. doi: 10.4103/jfmpc.jfmpc_869_19.
  5. Evans M, Ceriello A, Danne T, De Block C, DeVries JH, Lind M, Mathieu C, Nørgaard K, Renard E, Wilmot EG. Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. Diabetes Obes Metab. 2019;21(9): 2039–2047. doi: 10.1111/dom.13798.
  6. REPOSE Study Group. Relative effectiveness of insulin pump treatment over multiple daily injections and structured education during flexible intensive insulin treatment for type 1 diabetes: cluster randomised trial (REPOSE). BMJ. 2017;356:j1285. doi: 10.1136/bmj.j1285.
  7. Древаль АВ, Ковалева ЮА, Шестакова ТП. Помповая инсулинотерапия и непрерывное мониторирование гликемии. Клиническая практика и перспективы. M.: ГЭОТАР-Медиа; 2020. 336 c.
  8. Древаль АВ, Барсуков ИА, Шестакова ТП, Редькин ЮА, Древаль ОА, Тайсумова МВ, Демина АА. Помповая инсулинотерапия и непрерывное мониторирование гликемии: опыт клинической практики в рамках оказания высокотехнологичной медицинской помощи. Русский медицинский журнал. 2017;(1):3–8.
  9. Bode BW, Kyllo J, Kaufman FR. Pumping protocol: a guide to insulin pump therapy initiation [Internet]. Medtronic, Inc.; 2012. 36 p. Available from:
  10. Wizemann E, Renner R, Hepp K. Prospective evaluation of a standardized basal rate distribution for CSII in type 1 diabetes over 6 months. Diabetologie und Stoffwechsel. 2001;10:57.
  11. Siegmund T, Kolassa R, Thomas A. Clinical update on insulin pump therapy in combination with continuous glucose monitoring. Minerva Endocrinol. 2013;38(2):133–143.
  12. Шестакова МВ, Майоров АЮ, Филиппов ЮИ, Ибрагимова ЛИ, Пекарева ЕВ, Лаптев ДН, Глазунова АМ. Федеральные клинические рекомендации по помповой инсулинотерапии и непрерывному мониторированию гликемии у больных сахарным диабетом. Проект. Проблемы эндокринологии. 2015;61(6):55–78. doi: 10.14341/probl201561655-78.
  13. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631– 1640. doi: 10.2337/dc17-1600.
  14. Rilstone S, Reddy M, Oliver N. A Pilot Study of Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion (CSII) in Adults with Type 1 Diabetes (FIRST1D). J Diabetes Sci Technol. 2021;15(3):666–671. doi: 10.1177/1932296820906195.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2021 Barsukov I.A., Demina A.A., Dreval A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies